FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
ESMO 2025 preview – Astra joins the folate fray
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
